Healthy young mice treated with erythropoietin show lasting improved performance in learning and other higher brain functions. Researchers writing in the open access journal BMC Biology tested the cognitive effects of the growth factor, finding that it improved the sequential learning and memory components of a complex long-term cognitive task.
Hannelore Ehrenreich led a team of researchers from the Max Planck Institute of Experimental Medicine in Göttingen, Germany, who studied the mice. She said, "Erythropoietin has been in clinical use for over 20 years to treat patients with anemic conditions, ranging from renal failure to cancer. It has recently received attention for its apparent ability to improve cognitive function in people with schizophrenia and multiple sclerosis. Here, we sought to investigate erythropoietin's effects in healthy mice".
Ehrenreich and her colleagues tested the effects of erythropoietin on the ability of the mice to learn how to exploit an experimental set-up to receive sugared water. Over a series of learning stages, the mice were trained to get their treat by poking their noses into holes lit by LEDs, rather than into unlit holes, within a time limit. The mice that had been treated with recombinant human erythropoietin were significantly more likely to master the task than those that had not. According to Ehrenreich, "Treated mice showed superior performance in associative, operant and discriminant learning as well as in the initial training phases. Moreover, erythropoietin-treated mice demonstrated better task adaptation and higher performance stability".
The researchers conclude, "Further untangling of molecular mechanisms of erythropoietin action on higher cognitive functions may ultimately open new avenues for prevention strategies and therapeutic interventions in neuropsychiatric diseases".
Notes to Editors
1. Erythropoietin improves operant conditioning and stability of cognitive performance in mice
Ahmed El-Kordi, Konstantin Radyushkin and Hannelore Ehrenreich
During embargo, article available here: http://www.biomedcentral.com/imedia/3376926122535758_article.pdf?random=119865
After the embargo, article available at journal website: http://www.biomedcentral.com/bmcbiol/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
2. BMC Biology - the flagship biology journal of the BMC series - publishes research and methodology articles of special importance and broad interest in any area of biology and biomedical sciences. BMC Biology (ISSN 1741-7007) is covered by PubMed, MEDLINE, BIOSIS, CAS, Scopus, EMBASE, Zoological Record, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.